Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort

Experimental Biology and Medicine

Volumn 242, Issue 5, 2017, Pages 554-563

  Wolke, Carmen ^a   Teumer, Alexander ^a   Endlich, Karlhans ^a   Endlich, Nicole ^a   Rettig, Rainer ^a   Stracke, Sylvia ^a   Fiene, Beate ^a   Aymanns, Simone ^a   Felix, Stephan B ^a   Hannemann, Anke ^a   Lendeckel, Uwe ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

angiotensin converting enzyme 2; chronic kidney disease; dipeptidyl peptidase IV; estimated glomerular filtration rate; Protease activity; renin angiotensin system

Indexed keywords

AMINOPEPTIDASE; AMINOPEPTIDASE B; ANGIOTENSIN CONVERTING ENZYME 2; CYTOSOL AMINOPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL PEPTIDASE IV; GLUTAMYL AMINOPEPTIDASE; MICROSOMAL AMINOPEPTIDASE; PROLINE IMINOPEPTIDASE; PROTEINASE; CREATININE; CYSTYL AMINOPEPTIDASE; DPP4 PROTEIN, HUMAN; ENKEPHALIN DEGRADING ENZYME; LAP3 PROTEIN, HUMAN; LEUCYL-CYSTINYL AMINOPEPTIDASE; PEPTIDE HYDROLASE; PROLYL ENDOPEPTIDASE; SERINE PROTEINASE;

ADULT; AGED; ARTICLE; BIOCHEMICAL ANALYSIS; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OPTICAL DENSITY; BLOOD; ENZYMOLOGY; GLOMERULUS FILTRATION RATE; METABOLISM; MIDDLE AGED;

AGED; AMINOPEPTIDASES; ANTIGENS, CD13; CREATININE; CYSTINYL AMINOPEPTIDASE; DIPEPTIDYL PEPTIDASE 4; FEMALE; GLOMERULAR FILTRATION RATE; GLUTAMYL AMINOPEPTIDASE; HUMANS; LEUCYL AMINOPEPTIDASE; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; PEPTIDYL-DIPEPTIDASE A; RENAL INSUFFICIENCY, CHRONIC; SERINE ENDOPEPTIDASES;

EID: 85012899360     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370216684040     Document Type: Article

References (65)

1. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P. Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010; 31: 703–11.
2. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17–28.
3. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296–309.
4. Mujais SK, Story K, Brouillette J, Takano T, Soroka S, Franek C, Mendelssohn D, Finkelstein FO. Health-related quality of life in CKD Patients: correlates and evolution over time. Clin J Am Soc Nephrol 2009; 4: 1293–301.
5. Cruz DN, Schmidt-Ott KM, Vescovo G, House AA, Kellum JA, Ronco C, McCullough PA. Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contribut Nephrol 2013; 182: 117–36.
6. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, Suzuki F, Nagai Y, Nakano D, Hitomi H, Kitada K, Urushihara M, Kobori H, Kohno M, Nishiyama A. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 2012; 125: 1402–13.
7. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 2008; 19: 1459–62.
8. Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 2007; 22: 1314–22.
9. Capes SE, Gerstein HC, Negassa A, Yusuf S. Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care 2000; 23: 377–80.
10. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, de Zeeuw D, Trial CR. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003; 24: 412–412.
11. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992; 70: 479–87.
12. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ. CHARM Investigators and Committees. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009; 374: 543–50.
13. Bechtloff R, Goette A, Bukowska A, Kähne T, Peters B, Huth C, Wolke C, Lendeckel U. Gender and age-dependent differences in the bradykinin-degradation within the pericardial fluid of patients with coronary artery disease. Int J Cardiol 2011; 146: 164–70.
14. Blais C, Jr Drapeau G, Raymond P, Lamontagne D, Gervais N, Venneman I, Adam A. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am J Physiol 1997; 273: H2263–71.
15. Lendeckel U, Arndt M, Wrenger S, Nepple K, Huth C, Ansorge S, Klein HU, Goette A. Expression and activity of ectopeptidases in fibrillating human atria. J Mol Cell Cardiol 2001; 33: 1273–81.
16. Aroor A, Zuberek M, Duta C, Meuth A, Sowers JR, Whaley-Connell A, Nistala R. Angiotensin II stimulation of DPP4 activity regulates megalin in the proximal tubules. Int J Mol Sci 2016; 17: pii:E780–pii:E780.
17. Riera M, Marquez E, Clotet S, Gimeno J, Roca-Ho H, Lloreta J, Juanpere N, Batlle D, Pascual J, Soler MJ. Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse. PloS One 2014; 9: e84683–e84683.
18. Gangadharan Komala M, Gross S, Zaky A, Pollock C, Panchapakesan U. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes. Nephrology 2016; 21: 423–31.
19. Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De Meester I. Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 2001; 39: 155–9.
20. Lehmann HI, Wolke C, Malenke W, Röhl FW, Hammwöhner M, Bukowska A, Lendeckel U, Goette A. Enzymatic activity of DPIV and renin-angiotensin system (RAS) proteases in patients with left ventricular dysfunction and primary prevention implantable cardioverter/defibrillator (ICD). Int J Cardiol 2013; 168: 255–60.
21. Grabe HJ, Assel H, Bahls T, Dorr M, Endlich K, Endlich N, Erdmann P, Ewert R, Felix SB, Fiene B, Fischer T, Flessa S, Friedrich N, Gadebusch-Bondio M, Salazar MG, Hammer E, Haring R, Havemann C, Hecker M, Hoffmann W, Holtfreter B, Kacprowski T, Klein K, Kocher T, Kock H, Krafczyk J, Kuhn J, Langanke M, Lendeckel U, Lerch MM, Lieb W, Lorbeer R, Mayerle J, Meissner K, zu Schwabedissen HM, Nauck M, Ott K, Rathmann W, Rettig R, Richardt C, Salje K, Schminke U, Schulz A, Schwab M, Siegmund W, Stracke S, Suhre K, Ueffing M, Ungerer S, Volker U, Volzke H, Wallaschofski H, Werner V, Zygmunt MT, Kroemer HK. Cohort profile: Greifswald approach to individualized medicine (GANI_MED). J Transl Med 2014; 12: 144–144.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–70.
23. Delanaye P, Pottel H, Botev R, Inker LA, Levey AS. Con: should we abandon the use of the MDRD equation in favour of the CKD-EPI equation? Nephrol Dial Transplant 2013; 28: 1396–403. discussion 1403.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B (Methodological) 1995; 57: 289–300.
25. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238–43.
26. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002; 532: 107–10.
27. Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem 2005; 280: 39353–62.
28. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 2005; 280: 30113–9.
29. Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol 2016; 310: H137–52.
30. Xu C, Ding W, Zhang M, Gu Y. Protective effects of angiotensin-(1–7) administrated with an angiotensin-receptor blocker in a rat model of chronic kidney disease. Nephrology 2013; 18: 761–9.
31. Abe M, Oikawa O, Okada K, Soma M. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan. JRAAS 2015; 16: 159–64.
32. Fang F, Liu GC, Zhou X, Yang S, Reich HN, Williams V, Hu A, Pan J, Konvalinka A, Oudit GY, Scholey JW, John R. Loss of ACE2 exacerbates murine renal ischemia-reperfusion injury. PloS One 2013; 8: e71433–e71433.
33. Dilauro M, Zimpelmann J, Robertson SJ, Genest D, Burns KD. Effect of ACE2 and angiotensin-(1–7) in a mouse model of early chronic kidney disease. Am J Physiol 2010; 298: F1523–32.
34. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 2008; 74: 1610–6.
35. Lely AT, Hamming I, van Goor H, Navis GJ. Renal ACE2 expression in human kidney disease. J Pathol 2004; 204: 587–93.
36. Velez JC, Bland AM, Arthur JM, Raymond JR, Janech MG. Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes. Am J Physiol 2007; 293: F398–407.
37. Chong CP, Lim WK, Velkoska E, van Gaal WJ, Ryan JE, Savige J, Burrell LM. N-terminal pro-brain natriuretic peptide and angiotensin-converting enzyme-2 levels and their association with postoperative cardiac complications after emergency orthopedic surgery. Am J Cardiol 2012; 109: 1365–73.
38. Soro-Paavonen A, Gordin D, Forsblom C, Rosengard-Barlund M, Waden J, Thorn L, Sandholm N, Thomas MC, Groop PH, FinnDiane Study G. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens 2012; 30: 375–83.
39. Wang Y, Moreira Mda C, Heringer-Walther S, Ebermann L, Schultheiss HP, Wessel N, Siems WE, Walther T. Plasma ACE2 activity is an independent prognostic marker in Chagas’ disease and equally potent as BNP. J Cardiac Fail 2010; 16: 157–63.
40. Roberts MA, Velkoska E, Ierino FL, Burrell LM. Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease. Nephrol Dial Transplant 2013; 28: 2287–94.
41. Anguiano L, Riera M, Pascual J, Valdivielso JM, Barrios C, Betriu A, Mojal S, Fernandez E, Soler MJ, study N. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. Nephrol Dial Transplant 2015; 30: 1176–85.
42. Abe M, Maruyama N, Oikawa O, Maruyama T, Okada K, Soma M. Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease. Scand J Clin Lab Invest 2015; 75: 421–7.
43. Wang Z, Grigo C, Steinbeck J, von Horsten S, Amann K, Daniel C. Soluble DPP4 originates in part from bone marrow cells and not from the kidney. Peptides 2014; 57: 109–17.
44. Ansorge S, Schön E. Dipeptidyl peptidase IV (DP IV), a functional marker of the T lymphocyte system. Acta Histochem 1987; 82: 41–46.
45. Schön E, Ansorge S. Dipeptidyl peptidase IV in the immune system. Cytofluorometric evidence for induction of the enzyme on activated T lymphocytes. Biol Chem Hoppe-Seyler 1990; 371: 699–705.
46. Lendeckel U, Kähne T, Riemann D, Neubert K, Arndt M, Reinhold D. Review: the role of membrane peptidases in immune functions. Adv ExpMed Biol 2000; 477: 1–24.
47. Reinhold D, Bank U, Täger M, Ansorge S, Wrenger S, Thielitz A, Lendeckel U, Faust J, Neubert K, Brocke S. DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis. Front Biosci 2008; 13: 2356–63.
48. Carl-McGrath S, Lendeckel U, Ebert M, Wolter AB, Roessner A, Röcken C. The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer. Int J Oncol 2004; 25: 1223–32.
49. Boccardi V, Marano L, Rossetti RR, Rizzo MR, di Martino N, Paolisso G. Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker. BMC Cancer 2015; 15: 703–703.
50. Cordero OJ, Imbernon M, Chiara LD, Martinez-Zorzano VS, Ayude D, de la Cadena MP, Rodriguez-Berrocal FJ. Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol 2011; 2: 245–61.
51. Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 2009; 58: 1723–47.
52. Aso Y, Terasawa T, Kato K, Jojima T, Suzuki K, Iijima T, Kawagoe Y, Mikami S, Kubota Y, Inukai T, Kasai K. The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. J Lab Clin Med 2013; 162: 309–16.
53. Gorrell MD, Wang XM, Park J, Ajami K, Yu DM, Knott H, Seth D, McCaughan GW. Structure and function in dipeptidyl peptidase IV and related proteins. Adv Exp Med Biol 2006; 575: 45–54.
54. Kähne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D. Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med 1999; 4: 3–15.
55. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005; 48: 612–5.
56. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 2009; 200: 53–61.
57. Vallon V, Docherty NG. Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4. Exp Physiol 2014; 99: 1140–5.
58. Eun Lee J, Kim JE, Lee MH, Song HK, Ghee JY, Kang YS, Min HS, Kim HW, Cha JJ, Han JY, Han SY, Cha DR. DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury. Lab Invest 2016; 96: 547–60.
59. Jung E, Kim J, Ho Kim S, Kim S, Cho MH. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy. Eur J Pharmacol 2015; 761: 116–24.
60. Arruda-Junior DF, Martins FL, Dariolli R, Jensen L, Antonio EL, Dos Santos L, Tucci PJ, Girardi AC. Dipeptidyl peptidase IV inhibition exerts renoprotective effects in rats with established heart failure. Front Physiol 2016; 7: 293–293.
61. Gangadharan Komala M, Gross S, Zaky A, Pollock C, Panchapakesan U. Linagliptin limits high glucose induced conversion of latent to active TGFss through interaction with CIM6PR and limits renal tubulointerstitial fibronectin. PloS One 2015; 10: e0141143–e0141143.
62. Chen H, Roques BP, Fournie-Zaluski MC. Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett 1999; 9: 1511–6.
63. Ansorge S, Bank U, Heimburg A, Helmuth M, Koch G, Tadje J, Lendeckel U, Wolke C, Neubert K, Faust J, Fuchs P, Reinhold D, Thielitz A, Täger M. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 2009; 47: 253–61.
64. Schön E, Born I, Demuth HU, Faust J, Neubert K, Steinmetzer T, Barth A, Ansorge S. Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol Chem Hoppe-Seyler 1991; 372: 305–11.
65. Alves MF, Araujo MC, Juliano MA, Oliveira EM, Krieger JE, Casarini DE, Juliano L, Carmona AK. A continuous fluorescent assay for the determination of plasma and tissue angiotensin I-converting enzyme activity. Braz J Med Biol Res 2005; 38: 861–8.